



# Supplementary Figure S4.

**A**



**B**



**Supplementary Figure S4: Pertuzumab reverses NRG1-mediated resistance against erdafitinib.** (A) Tumor volumes RT4 NRG1-tumors in CB17-SCID mice treated with vehicle, 5 mg/kg erdafitinib, 5 mg/kg pertuz, or combinational treatment. Data are represented as individual values in the left graph and as mean  $\pm$  SD in the right graph. (B) Proliferation analysis of RT4 (left) and RT112 (right) cells treated with 10 nM erdafitinib in media ctrl or CM of 3T3-L1 cells. Pertuzumab was added (or not added) on day 3 of treatment. Crystal violet staining was performed on day 0, 3, 7. Data are normalized to untreated cells at the first day of treatment (day 0). "O.D": optical density. Three biological replicates were performed. Data are represented as mean  $\pm$  SD.